CONTENTS:
- Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs [Editorial]. Grebely J., Bruggmann P., Treloar C., Byrne J., Rhodes T., Dore G.J., p. 893-898.
- Enhancing the detection and management of acute hepatitis C virus infection. Martinello M., Matthews G.V., p. 899-910.
- Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis. Smith D.J., Combellick J., Jordan A.E., Hagan H., p. 911-921.
- Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum. Meyer J.P., Moghimi Y., Marcus R., Lim J.K., Litwin A.H., Altice F.L., p. 922-935.
- Health-Related Quality of Life for individuals with hepatitis C: A narrative review. Whiteley D., Elliott L., Cunningham-Burley S., Whittaker A., p. 936-949.
- Defining populations and injecting parameters among people who inject drugs: Implications for the assessment of hepatitis C treatment programs [Commentary]. Larney S., Grebely J., Hickman M., De Angelis D., Dore G.J., Degenhardt L., p. 950-957.
- Hepatitis C transmission and treatment as prevention - The role of the injecting network [Commentary]. Hellard M., McBryde E., Sacks Davis R., Rolls D.A., Higgs P., Aitken C., et al., p. 958-962.
- The promise of treatment as prevention for hepatitis C: Meeting the needs of people who inject drugs? [Commentary] Harris M., Albers E., Swan T., p. 963-969.
- Hepatitis C Virus seroconversion among persons who inject drugs in relation to primary care physician visiting: The potential role of primary healthcare in a combined approach to Hepatitis C prevention. Artenie A.A., Roy É., Zang G., Jutras-Aswad D., Bamvita J.-M., Puzhko S., et al., p. 970-975.
- Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. Alavi M., Spelman T., Matthews G.V., Haber P.S., Day C., van Beek I., et al., p. 976-983.
- Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study. Marshall A.D., Micallef M., Erratt A., Telenta J., Treloar C., Everingham H., et al., p. 984-991.
- Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia. Treloar C., Rance J., Bath N., Everingham H., Micallef M., Day C., et al., p. 992-998.
- Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia. Keats J., Micallef M., Grebely J., Hazelwood S., Everingham H., Shrestha N., et al., p. 999-1006.
- Beyond viral response: A prospective evaluation of a community-based, multi-disciplinary, peer-driven model of HCV treatment and support. Mason K., Dodd Z., Sockalingam S., Altenberg J., Meaney C., Millson P., et al., p. 1007-1013.
- Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program. Litwin A.H., Soloway I.J., Cockerham-Colas L., Reynoso S., Heo M., Tenore C., et al., p. 1014-1019.
- From principles to practice: Description of a novel equity-based HCV primary care treatment model for PWID. Milne R., Price M., Wallace B., Drost A., Haigh-Gidora I., Nezil F.A., et al., p. 1020-1027.
- Recommendations for the management of hepatitis C virus infection among people who inject drugs. Grebely J., Robaeys G., Bruggmann P., Aghemo A., Backmund M., Bruneau J., et al., p. 1028-1038.